Перейти к содержанию

Ptc Therapeutics, Inc. (PTCT) stock: revenue, earnings & dividend

Ptc Therapeutics, Inc. (PTCT, Nasdaq): revenue, earnings, dividend and balance sheet from official SEC filings.

Stock screener PTCT · Nasdaq Pharma & Biotech US-NJ

Key figures

Fiscal year
2025
Revenue
1.73 bn $
Revenue growth
114.5 %
Revenue growth 5y (p.a.)
35.4 %
Net income
683 m $
Net margin
39.5 %
Operating margin
50.1 %
Earnings per share (diluted)
7.78 $
Dividend per share
–
Payout ratio
–
Consecutive dividend years
–
Consecutive dividend raises
–
Dividend growth 5y (p.a.)
–
Total assets
2.9 bn $
Equity
-205.31 m $
Equity ratio
-7.1 %
Return on equity
–
Cash
985 m $
Operating cash flow
711 m $
Free cash flow
702 m $
Shares outstanding
83,544,284

History

Revenue by fiscal year

2016 82.7 m $
2017 194 m $
2018 265 m $
2019 307 m $
2020 381 m $
2021 539 m $
2022 699 m $
2023 938 m $
2024 807 m $
2025 1.73 bn $

Net income by fiscal year

2016 -142.11 m $
2017 -79 m $
2018 -128.08 m $
2019 -251.58 m $
2020 -438.16 m $
2021 -523.9 m $
2022 -559 m $
2023 -626.6 m $
2024 -363.3 m $
2025 683 m $
YearRevenueNet incomeEPSDividend per shareOperating cash flow
20251.73 bn $683 m $7.78 $–711 m $
2024807 m $-363.3 m $-4.73 $–-107.69 m $
2023938 m $-626.6 m $-8.37 $–-158.42 m $
2022699 m $-559 m $-7.79 $–-356.65 m $
2021539 m $-523.9 m $-7.43 $–-251.33 m $
2020381 m $-438.16 m $-6.64 $–-194.07 m $
2019307 m $-251.58 m $-4.27 $–-98.64 m $
2018265 m $-128.08 m $––-27.64 m $
2017194 m $-79 m $––-10.06 m $
201682.7 m $-142.11 m $––-103.57 m $

Data from XBRL filings at the SEC, processed automatically, no guarantee. Not investment advice. All filings at the SEC (EDGAR)